Lifetime costs of CLL by first-line treatment selection: continuous monotherapy zanubrutinib versus venetoclax-based regimens

ASH 2026 • CLL • Zanubrutinib • Poster

Pier Luigi Zinzani, MD PhD

DISCLAIMER

The contents of the presentation are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.

SUMMARY

This economic modeling analysis estimated total lifetime costs associated with first-line zanubrutinib monotherapy versus approved fixed-duration venetoclax-based regimens (venetoclax plus obinutuzumab [V+O], ibrutinib plus venetoclax [I+V], and acalabrutinib plus venetoclax [A+V]) in patients with treatment-naïve chronic lymphocytic leukemia (CLL) over a lifetime horizon. A three-state Markov model incorporating progression-free disease, progressed disease, and death was developed, with health state transitions using published clinical data. Patients were assumed to receive venetoclax plus rituximab following first-line zanubrutinib and zanubrutinib following first-line venetoclax-based regimens, using published trial data to inform the duration of treatment (MURANO and ALPINE, respectively). Given the prominence of fixed-duration regimens in Europe, costs were estimated across Germany, Italy, and France. Across these countries, modeled lifetime costs were lowest for treatment strategies with zanubrutinib. Across all countries, drug costs (both frontline and subsequent treatment) represented the greatest proportion of costs. In Germany, first-line drug costs accounted for 56%, 21%, 31%, and 29% of total lifetime costs for a CLL treatment strategy starting with zanubrutinib, V+O, I+V, and A+V, respectively. Second-line drug costs were proportionally lower for zanubrutinib (25%; versus V+O, I+V, and A+V: 52%, 50%, and 53%, respectively); similar patterns were observed for Italy and France. Although frontline drug acquisition costs were higher with zanubrutinib, these costs were offset over the lifetime horizon by lower subsequent treatment costs, lower tumor lysis syndrome prophylaxis management costs, lower adverse-event management costs, and reduced societal costs. Results remained consistent across sensitivity analyses.

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed